CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to KRYS

Open Label Topical Beremagene Geperpavec (B-VEC)

Phase 3
Krystal Biotech, Inc. (KRYS)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

3 competitors in Dystrophic Epidermolysis Bullosa

View Full Landscape
Drug Information

Target Indication

Dystrophic Epidermolysis Bullosa

Clinical Trial

NCT04917874

Last updated: 12/4/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.